Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 33,205 matching trials from the live ClinicalTrials.gov search.
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.4 Challenge Pool CIN-1, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Tiragolumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Hot Springs, Arkansas • Clovis, California • Duarte, California + 26 more
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 Booster Incentives

NCT05648773
Conditions
Booster Message, Booster Message + Financial Incentive
Interventions
Messaging, Financial Incentive, Placebo
Behavioral · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
57,893 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Martinez, California
Completed Phase 2 Interventional Results available

Citalopram for Cocaine Dependence

NCT01535573
Conditions
Cocaine Dependence
Interventions
Citalopram, Placebo
Drug
Lead sponsor
Joy Schmitz
Other
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prader-Willi Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Irvine, California • Gainesville, Florida • Kansas City, Kansas + 2 more
Conditions
Type 2 Diabetes Mellitus
Interventions
GK1-399 (formerly TTP399), Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • Chula Vista, California • DeLand, Florida + 8 more
Conditions
Early Alzheimer´s Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
Conditions
Dengue Fever
Interventions
rDEN4delta30-200,201, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Schizophrenia
Interventions
SKL15508, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Glendale, California
Completed Phase 1Phase 2 Interventional Results available

DAW1033D in Obstructive Sleep Apnea

NCT03383887
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Placebo oral capsule, DAW1033D oral capsule
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bleeding From Teeth, Bleeding Prophylaxis
Interventions
Tranexamic acid
Drug
Lead sponsor
Hyloris Developments
Industry
Eligibility
18 Years to 99 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Loma Linda, California • Stamford, Connecticut • Millcreek, Utah + 1 more
Conditions
Schizophrenia
Interventions
CTP-692, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
26
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 21 more
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Artesia, California • Kansas City, Missouri • St Louis, Missouri + 4 more
Conditions
Cancer, Myeloid Neoplasm
Interventions
GO-EXCAP Mobile App, Behavioral Placebo Control
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, New York
Conditions
Schizophrenia
Interventions
Bifeprunox, Quetiapine
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
69
States / cities
Anaheim, California • Cerritos, California • Costa Mesa, California + 52 more
Conditions
Overweight, Obesity
Interventions
Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
45
States / cities
Lancaster, California • Palm Springs, California • Pomona, California + 40 more
Terminated Phase 2 Interventional Results available

A Study of IMR-687 in Subjects With Sickle Cell Disease

NCT04474314
Conditions
Sickle Cell Disease
Interventions
IMR-687, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 11 more
Conditions
Wounds and Injuries
Interventions
AR/101, Placebo
Drug
Lead sponsor
Arava Bio Tech Ltd.
Industry
Eligibility
25 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Substance Abuse, HIV Infections
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Francisco, California
Conditions
Schizophrenia
Interventions
Oxytocin: 24IU - 168 IU, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Recruiting Not applicable Interventional Accepts healthy volunteers

Assessing the Short-Term Effects of Multi-Fiber Supplementation on Gut Health

NCT07787026
Conditions
Mixed Fiber Supplementation for Healthy Adults
Interventions
Prebiotic, Placebo
Dietary Supplement
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
62
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more
Conditions
Congestive Heart Failure
Interventions
SLV320
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
10
States / cities
Whittier, California • Largo, Florida • Miami, Florida + 7 more
Completed Phase 1Phase 2 Interventional Results available

Mifepristone for the Prevention of Relapses of Alcohol Drinking

NCT02243709
Conditions
Alcohol Use Disorders (AUD)
Interventions
Mifepristone 600-mg/day or placebo for a week
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island